Chinese pharmaceutical companies are eyeing a lucrative commercial market set to materialise upon the patent expiry for Novo Nordisk’s blockbuster weight loss and type 2 diabetes (T2D) drug semaglutide.
While patents for the glucagon-like peptide-1 receptor agonist (GLP-1RA), known under the brand names Wegovy and Ozempic for weight loss and T2D treatment, respectively, are not set to expire until the early 2030s, protection against generics for the drug in China lapses in 2026.
GlobalData pharma analyst Nadim Anwer said: “The semaglutide patent cliff in China represents a paradigm shift that will broaden access to life-changing GLP-1RA therapies while creating a new competitive landscape dominated by local players. It will drive increased competition and lower prices.”
China has emerged as a key research and development (R&D) hub in the past decade. Many big pharma companies have ventured into biotechs in the country in search of the next blockbusters in oncologic, cardiometabolic, and autoimmune indications, amongst others.
However, the gaping hole soon to be created by semaglutide’s patent expiry will offer an opportunity for Chinese biotechs to commercialise drugs in a high-growth area closer to home. The International Diabetes Federation estimates that nearly 148 million adults in China have diabetes.
Anwer added: “Chinese drugmakers face a transformative opportunity once semaglutide’s patent protection ends, positioning them to lead the future wave of diabetes and obesity treatment within China.
“Winning this race demands superior production capabilities, precise timing for market launch, and strong regulatory expertise. Chinese manufacturers are well-positioned to challenge established players and drive the transition in China from monopolistic pricing to more dynamic market competition.”
The pricing of GLP-1RAs has been the subject of scrutiny this year. There is a wide range of price points for Wegovy and Ozempic in the US in what has been a dynamic cost model, due to separate pressures from President Donald Trump and the compounded market. Novo’s main rival in the space, Eli Lilly, increased the price of Mounjaro (tirzepatide) in the UK in the past month to “better reflect market conditions”.
The first GLP-1RA generic was approved in the US last week when the US Food and Drug Administration (FDA) greenlit Teva’s drug referencing Novo Nordisk’s Saxenda (liraglutide). However, Saxenda is not one of the new-generation weight loss drugs and is far less popular than semaglutide and Lilly’s tirzepatide.
While it is therefore unclear as to how the Chinese market will play out, given the lack of precedent, patent losses with blockbuster drugs in other disease areas offer a clue. Generics and biosimilars can be on average 80% cheaper, meaning patients often switch away from the more expensive branded alternative.
